Zambia
Tuberculosis profile
| High HIV burden |
Population  2012 14 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.9 (1.4–7.7) 28 (9.8–55)
Mortality (HIV+TB only) 7.6 (6.2–8.9) 54 (44–63)
Prevalence  (includes HIV+TB) 55 (28–90) 388 (197–642)
Incidence  (includes HIV+TB) 60 (54–66) 427 (385–470)
Incidence (HIV+TB only) 35 (32–39) 251 (226–276)
Case detection, all forms (%) 68 (62–75)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 12 645 (33) Relapse 1 857 (29)
Smear-negative 17 050 (44) Treatment after failure 213 (3)
Smear-unknown / not done     Treatment after default 509 (8)
Extrapulmonary 9 174 (24) Other 3 829 (60)
Other          
Total new 38 869   Total retreatment 6 408  
           
Other (history unknown)          
Total new and relapse 40 726   Total cases notified 45 277  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.4 1.3
Age < 15 321 1 637 1 374
Laboratories 2012
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population)  
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 45 269 (100)
HIV-positive TB patients 24 309 (54)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 22 614 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 14 471 (60)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.33 (0.04–1.2) 8.1 (4.1–14)
MDR-TB cases among notified pulmonary
TB cases
98 (12–350) 520 (260–900)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     80
Patients started on MDR-TB treatment     97
Financing TB control 2013
National TB programme budget (US$ millions) 39
% Funded domestically 27%
% Funded internationally 76%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data